These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 16111085)
1. 5HT3-receptor antagonists as antiemetics in cancer. Drug Ther Bull; 2005 Aug; 43(8):57-62. PubMed ID: 16111085 [TBL] [Abstract][Full Text] [Related]
2. [Palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in Italy: pharmacologic, clinical and economic aspects]. Pradelli L; Eandi M Tumori; 2008; 94(2):suppl 26-32. PubMed ID: 18564623 [No Abstract] [Full Text] [Related]
3. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Rubenstein EB Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194 [TBL] [Abstract][Full Text] [Related]
4. [Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy]. Di Maio M; Gallo C; Perrone F Tumori; 2008; 94(2):suppl 14-22. PubMed ID: 18564621 [No Abstract] [Full Text] [Related]
5. The role of 5-HT3 receptor antagonists in preventing postoperative nausea and vomiting. Board T; Board R AORN J; 2006 Jan; 83(1):209-16, 219-20. PubMed ID: 16528908 [TBL] [Abstract][Full Text] [Related]
6. Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy. Hamadani M; Awab A; Chaudhary L; Tfayli A J Oncol Pharm Pract; 2006 Jun; 12(2):67-8. PubMed ID: 16984743 [No Abstract] [Full Text] [Related]
7. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study. Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447 [TBL] [Abstract][Full Text] [Related]
8. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Morrow GR; Hickok JT; Rosenthal SN Cancer; 1995 Aug; 76(3):343-57. PubMed ID: 8625113 [TBL] [Abstract][Full Text] [Related]
9. Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron. Kidgell AE; Butcher ME; Brown GW Cancer Treat Rev; 1990 Sep; 17(2-3):311-7. PubMed ID: 2176933 [No Abstract] [Full Text] [Related]
10. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis. Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361 [TBL] [Abstract][Full Text] [Related]
11. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Stiakaki E; Savvas S; Lydaki E; Bolonaki I; Kouvidi E; Dimitriou H; Kambourakis A; Kalmanti M Pediatr Hematol Oncol; 1999; 16(2):101-8. PubMed ID: 10100270 [TBL] [Abstract][Full Text] [Related]
12. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Jordan K; Hinke A; Grothey A; Voigt W; Arnold D; Wolf HH; Schmoll HJ Support Care Cancer; 2007 Sep; 15(9):1023-33. PubMed ID: 17205281 [TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of two antiemetic combinations palonosetron dexamethasone versus ondansetron dexamethasone in chemotherapy of head and neck cancer. Kaushal J; Gupta MC; Kaushal V; Bhutani G; Dhankar R; Atri R; Verma S Singapore Med J; 2010 Nov; 51(11):871-5. PubMed ID: 21140114 [TBL] [Abstract][Full Text] [Related]
14. Serotonin antagonists for nausea and vomiting. Gastroenterol Nurs; 2014; 37(2):184-6. PubMed ID: 24691090 [No Abstract] [Full Text] [Related]